This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Company News for Oct 17, 2024
by Zacks Equity Research
Companies In The News Are: ABT, CFG, FHN, IBKR.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
by Zacks Equity Research
ABT delivers a strong underlying base business performance in the third quarter of 2024.
Quarterly Earnings Reports Summary
by Zacks Equity Research
Quarterly Earnings Reports Summary
The Zacks Analyst Blog Highlights Alibaba, Linde, Abbott Laboratories and Value Line
by Zacks Equity Research
Alibaba, Linde, Abbott Laboratories and Value Line are part of the Zacks top Analyst Blog.
Imports/Exports Lower; Morgan Stanley, Abbott Beat in Q3
by Mark Vickery
Both Imports and Exports were deeper into the negative than expected. Meanwhile, MS, ABT and USB all beat of Q3 earnings.
Zacks Investment Ideas feature highlights: Abbott Laboratories, Equifax and SL Green Realty
by Zacks Equity Research
Abbott Laboratories, Equifax and SL Green Realty are part of the Zacks Investment Ideas article.
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0.83% and 0.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Markets Unwind China, Oil Prices; UAL, IBKR, JBHT Report Q3
by Mark Vickery
While the Dow and S&P 500 rolled back closing highs, United (UAL) and J.B. Hunt (JBHT) are up on strong Q3 figures.
Top Analyst Reports for Alibaba, Linde & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Linde plc (LIN) and Abbott Laboratories (ABT), as well as a micro-cap stock Value Line, Inc. (VALU).
3 Top-Rated Stocks to Watch as Earnings Approach: ABT, EFX, SLG
by Shaun Pruitt
Sporting a Zacks Rank #2 (Buy), here are three top-rated stocks that investors will want to consider as their Q3 results approach on Wednesday, October 16.
UnitedHealth Q3 Earnings Beat on Domestic Commercial Business
by Zacks Equity Research
UNH's third-quarter earnings benefit on the back of client wins in the Optum Rx sub-unit, partly offset by an elevated operating expense level.
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Iridium Gearing Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Iridium's third-quarter performance is likely to have benefited from momentum in commercial service revenues and increasing subscriber base.
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
by Zacks Equity Research
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
What to Expect From Badger Meter Stock Ahead of its Q3 Earnings
by Zacks Equity Research
BMI's third-quarter performance is likely to have benefited from increased demand for its digital smart water solutions.
QIAGEN's TB Testing Business Gets New Exposure at Global Summit
by Zacks Equity Research
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
Abbott (ABT) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
by Zacks Equity Research
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
by Urmimala Biswas
The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Bet on HOLX Stock This Breast Cancer Awareness Month?
by Moumi Mondal
Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.